This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas (BCC) in Gorlin Syndrome Patients (BCC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
PellePharm, Inc.
ClinicalTrials.gov Identifier:
NCT02762084
First received: April 27, 2016
Last updated: May 5, 2017
Last verified: May 2017
  Purpose
Multicenter, double-blind, randomized, vehicle-controlled evaluates the efficacy and safety of patidegib gel, 2% and 4% in comparison with vehicle in subjects at least 18 years of age that meet the diagnostic criteria for basal cell nevus syndrome (BCNS). Subjects will be randomized to receive patidegib gel 4%, patidegib gel 2%, or the vehicle gel for a 26 week treatment period.

Condition Intervention Phase
Basal Cell Nevus Syndrome Drug: patidegib Drug: vehicle gel Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal (SEB) Cell Carcinomas in Gorlin Syndrome Patients

Resource links provided by NLM:


Further study details as provided by PellePharm, Inc.:

Primary Outcome Measures:
  • Clinical efficacy: change from baseline in greatest diameter treatment-targeted surgically eligible basal cell carcinomas [ Time Frame: Baseline and Weeks 2, 6, 10, 14, 18, 22, and 26 ]
    To evaluate the clinical efficacy of patidegib as defined by the percent decrease in greatest diameter of baseline treatment targeted surgically eligible basal cell carcinomas after 26 weeks of treatment.

  • Molecular efficacy: change from baseline of reduction in the the hedgehog (HH) signaling pathway target gene GLI1 [ Time Frame: Baseline and 6 weeks ]
    To evaluate the molecular efficacy of treatment as defined by reduction in the HH signaling pathway target gene GLI1 after treatment with patidegib gel 2% or 4% or vehicle applied twice daily for 6 weeks to treatment-targeted SEBs.

  • Change in safety and tolerability assessment of treatment with patidegib gel [ Time Frame: Screening, Baseline, Weeks 2, 6, 10, 14, 18, 22, and 26 ]
    From baseline, subjects will be assessed for the occurrence of new and ongoing adverse events. AEs present at any visit will be followed to resolution or until clinically stable as determined by the Investigator. Routine safety laboratory tests will be performed at Screening, Baseline, Weeks 6, 14, and 26.


Secondary Outcome Measures:
  • Clinical efficacy: change from baseline in central facial SEBs [ Time Frame: Baseline, Weeks 2, 6, 10, 14, 18, 22, and 26 ]
    To evaluate the clinical efficacy of treatment as defined by percent decrease in greatest diameter of baseline central facial SEBs.

  • Change from baseline of frequency of new SEBs on the face [ Time Frame: Baseline, Weeks 2, 6, 10, 14, 18, 22, and 26 ]
    To evaluate the frequency of new SEBs on the face.

  • Change from baseline in the proportion of non-central facial BCCs [ Time Frame: Baseline and Weeks 6, 10, 14, 18, 22, and 26 ]
    To evaluate the proportion of non-central facial BCCs that at Baseline and/or Week 2 visit were less than 5 mm in greatest diameter but by the Week 6, 10, 14, 18, 22, or 26 visit have become greater than 5 mm in greatest diameter.

  • Change from baseline in the proportion of baseline treatment targeted SEBs [ Time Frame: Baseline, Weeks 2, 6, 10, 14, 18, 22, and 26 ]
    To evaluate the proportion of baseline treatment targeted SEBs that at the end of 26 weeks of treatment are no longer large enough to be classified as SEBs


Other Outcome Measures:
  • Change from baseline of an investigator static global tumor assessment (ISGTA) [ Time Frame: Baseline, Weeks 2, 6, 10, 14, 18, 22, and 26 ]
    To evaluate the utility of an ISGTA in assessing the proportion of baseline treatment targeted SEBs that are evaluated as being clear or almost clear.


Enrollment: 17
Actual Study Start Date: June 6, 2016
Study Completion Date: April 24, 2017
Primary Completion Date: April 24, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: patidegib gel 2%,
patidegib gel 2%, applied topically, twice daily for 26 weeks
Drug: patidegib
patidegib gel 2% or 4%, applied topically, twice daily for 26 weeks
Other Name: study drug
Experimental: patidegib gel 4%,
patidegib gel 4%, applied topically, twice daily for 26 weeks
Drug: patidegib
patidegib gel 2% or 4%, applied topically, twice daily for 26 weeks
Other Name: study drug
Placebo Comparator: vehicle gel
vehicle gel, applied topically, twice daily for 26 weeks
Drug: vehicle gel
vehicle gel, applied topically, twice daily for 26 weeks
Other Name: Placebo

Detailed Description:

This is a multicenter, double-blind, randomized, vehicle-controlled study designed to compare the efficacy and safety of patidegib gel, 2% and 4% in comparison with that of vehicle. To be eligible for the study, subjects must be at least 18 years of age and must meet the diagnostic criteria for basal cell nevus syndrome BCNS.

Approximately 18 subjects who meet the study entry criteria will be randomized in a 1:1:1 ratio to receive patidegib gel 2%, patidegib gel 4%, vehicle gel. One or two tubes of the assigned study drug will be dispensed to the subject at the Baseline visit. Additional tubes will be dispensed at subsequent visits through Week 22. The study drug will be applied topically to the entire face as well as to treatment-targeted surgically eligible basal cell carcinomas (SEBs) at other anatomical sites twice daily for 26 weeks of treatment.

Information on reported and observed adverse events will be obtained at each visit. An abbreviated physical examination will be performed at Baseline, Week 14, and Week 26.

At Baseline and Weeks 2, 6, 10, 14, 18, 22, and 26, all visible BCCs (excluding areas below the knees) will be identified by the Investigator, circled in ink, photographed, measured, and recorded on a body diagram. Treatment targeted SEBs are defined as the five SEBs on the face and/or other anatomical areas identified at Baseline as SEBs will be treated during the 26 week treatment phase. If a subject has 5 eligible previously untreated facial SEBs (excluding tumors on nose and eyelids) these tumors will be the subject's 5 baseline treatment targeted SEBs and non-facial baseline SEBs will not be treated with study medication.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The subject is from 18 to 85 years of age, inclusive.
  2. The subject must provide written informed consent prior to any study procedures.
  3. The subject must meet diagnostic criteria for BCNS including major criterion #3a plus one additional major criterion or major criterion #3a plus two of the minor criteria outlined below:

    Major Criteria:

    • More than 2 histologically confirmed BCCs or one under the age of 20 years
    • Odontogenic keratocysts of the jaw proven by histology
    • Three or more palmar and/or plantar pits
    • Bilamellar calcification of the falx cerebri (if less than 20 years old)
    • Fused, bifid, or markedly splayed ribs.
    • First degree relative with basal cell nevus syndrome
    • PTCH1 gene mutation in normal tissue

    Minor Criteria

    • Macrocephaly
    • Congenital malformations: cleft lip or palate, frontal bossing, "coarse face", moderate or severe hypertelorism
    • Skeletal abnormalities: sprengel deformity, marked pectus deformity, or marked syndactyly of the digits
    • Radiological abnormalities: bridging of the sella turcica, vertebral anomalies such as hemivertebrae, fusion or elongation of the vertebral bodies, modeling defects of the hands and feet, or flame shaped lucencies of the hands or feet
    • Ovarian fibroma
    • Medulloblastoma
  4. The subject must have a history of at least 10 BCCs in toto present at Baseline and/or treated within 24 months prior to screening.
  5. The subject has at Baseline a total of at least 5 previously untreated SEBs (greatest diameter 5 mm or greater on the face excluding the nose and periorbital skin, 9 mm or greater on non-facial areas excluding the skin below the knees), as documented clinically by the Investigator at Baseline. Untreated is define as no previous surgical or topical or intralesional drug treatment. Previous treatment with systemically administered drugs more than 6 months prior to Baseline is not considered previous treatment as long as there was no clinical evidence of resistance to oral HH (e.g., vismodegib, patidegib, and sonidegib) inhibitors. Baseline treatment targeted SEBs must not exceed a diameter of > 2cm. At least one of these tumors must be appropriate for a 2 mm punch biopsy for biomarker analysis at Baseline and Week 6 visits. If a subject has 5 or more facial, excluding periorbital and nasal skin, SEBs at Baseline, non-facial SEBs will not be treatment targeted SEBs.
  6. The subject is willing to have SEBs biopsied for biomarkers and plasma to be collected to measure drug levels as required in the protocol.
  7. The subject is willing to abstain from application of non-study topical prescription and over the counter medications to facial skin and within 5 cm of treatment targeted SEBs at other anatomical areas for the duration of the study except as prescribed by the Investigator. Moisturizers and emollients are allowable. Subjects will be encouraged to use sunscreen with a sunscreen protection factor (SPF 15 or higher) at least once daily on all exposed skin sites.
  8. Female subjects must have a negative serum pregnancy test at Screening.
  9. If the subject is a male with a female sexual partner who is of childbearing potential the couple is willing to use two effective methods of birth control during the duration of the trial and for one month after the last application of the gel. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months, must agree to use two effective methods of contraception for the duration of the study and at least 1 month after the last study drug application. The two forms of birth control authorized are defined as the use of a barrier method of contraception (condom with spermicide) in association with one of the following methods of birth control: bilateral tubal ligation; combined oral contraceptives (estrogens and progesterone) or implanted or injectable contraceptives with a stable dose for at least 1 month prior to Baseline; hormonal intra-uterine device (IUD) inserted at least 1 month prior to Baseline.
  10. The subject is willing to contact the study center after each primary skin care physician (PSCP) visit to provide the study center details of the visit and any treatment of skin tumors.
  11. The subject is willing to forego treatment of the treatment targeted baseline SEBs except when the Investigator and/or primary care giver believes that delay in treatment potentially might compromise the health of the subject.

Exclusion Criteria:

  1. The subject is a woman of childbearing potential. This proscription is based on the key role of the HH pathway in embryogenesis, the known preclinical teratogenic effects of systemic cyclopamine, a naturally occurring inhibitor of smoothened, and the unknown level of systemic exposure following topical application in humans. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months.
  2. The subject has used topical products to the face or within 5 cm of a treatment targeted SEB or systemic therapies that might interfere with the evaluation of the study medication during the study. Specifically these include the use of:

    • Topical glucocorticoids 30 days prior to screening
    • Retinoids (e.g., etretinate, isotretinoin, tazarotene, tretinoin, adapalene) systemically or topically or > 5% of an alphahydroxy acid (e.g., glycolic acid, lactic acid) or 5-fluorouracil or imiquimod (except as topical treatment to discrete BCCs) systemically or topically to the skin during the six months prior to entry.
    • Systemic chemotherapy within one year prior to screening. (Note: field therapy with topically applied treatments can be done as long as they are not applied within 5 cm of a treatment targeted tumor).
    • Known inhibitors of the HH signaling pathway (e.g., vismodegib, patidegib, and sonidegib) topically or systemically within 6 months of entry into the study.
  3. The subject has a history of hypersensitivity to any of the ingredients in the study medication formulation.
  4. The subject is unable or unwilling to make a good faith effort to return for all follow-up visits and tests.
  5. The subject has uncontrolled systemic disease.
  6. The subject has clinically important history of liver disease, including viral hepatitis, current alcohol abuse, or cirrhosis.
  7. The subject has any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study. This includes history of other skin conditions or diseases, metabolic dysfunction, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications.
  8. The subject has a history of invasive cancer within the past five years excluding non-melanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of breast, or chronic lymphocytic lymphoma (Stage 0).
  9. The subject has current, recent (within 4 weeks of Baseline visit), or planned participation in an experimental drug study while enrolled in this study.
  10. Female sexual partner(s) of male subjects who are unwilling or unable to comply with pregnancy prevention measures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02762084

Locations
United Kingdom
Royal London Hospital
London, United Kingdom
Manchester Royal Infirmary
Manchester, United Kingdom
Sponsors and Collaborators
PellePharm, Inc.
Investigators
Principal Investigator: John Lear, MD Manchester Royal Infirmary
  More Information

Responsible Party: PellePharm, Inc.
ClinicalTrials.gov Identifier: NCT02762084     History of Changes
Other Study ID Numbers: Pelle-926-201
2015-004274-15 ( EudraCT Number )
Study First Received: April 27, 2016
Last Updated: May 5, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by PellePharm, Inc.:
Gorlin Syndrome
Basal Cell
Nevus Syndrome
BCNS
nevoid basal cell carcinoma syndrome
Basal cell carcinoma
Hedgehog
Surgically Eligible Basal Cell Carcinomas

Additional relevant MeSH terms:
Syndrome
Carcinoma
Carcinoma, Basal Cell
Basal Cell Nevus Syndrome
Disease
Pathologic Processes
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell
Odontogenic Cysts
Jaw Cysts
Bone Cysts
Cysts
Neoplastic Syndromes, Hereditary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Jaw Diseases
Stomatognathic Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on June 23, 2017